-
Mashup Score: 0VJOncology – The video journal of oncology - 2 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4VJOncology – The video journal of oncology - 2 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢1 week until #ESMOBreast22! Make sure to tune into https://t.co/ys1d8plZme where we will be posting exclusive interviews with the leading clinicians and researchers in #BreastCancer from the meeting! #BCSM @myESMO https://t.co/2fbaPjiyq2
-
Get ready for #ESMOBreast22 with our feature on key updates in from #ESMOBreast21 at https://t.co/ys1d8plZme! Read here 👉https://t.co/wNGbEOXnel👈 #BCSM #BreastCancer @myESMO https://t.co/8L7cWLJQNG
-
-
Mashup Score: 2VJOncology – The video journal of oncology - 2 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out https://t.co/ys1d8plZme for highlights from #ELCC22, including interviews with top speakers on meeting the unmet needs for patients living with #LungCancer! @myESMO #LCsm #NSCLC #Mesothelioma https://t.co/6g3mcoACRG
-
📣Join #ESMOBreast22 3rd-5th May for the latest developments in #BreastCancer! 🌟In preparation, catch up with highlights from #ESMOBreast21 with https://t.co/ys1d8plZme 👉https://t.co/5tcgwETMyu #BCSM #Oncology @myESMO https://t.co/05COkq3mDb
-
-
Mashup Score: 2VJOncology – The video journal of oncology - 2 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join #AACR22 today for talks on cancer survivorship, AI in cancer imaging and more! 📢Check out https://t.co/ys1d8pDAKO now for exclusive coverage on the event! #BCsm #LCsm #GUsm #Pancsm @AACR https://t.co/ZAyVHsmMM4
-
📣#ESMOBreast22 begins on May 3rd! Join for three days of discussion on the latest in #BreastCancer! In the meantime, catch the highlights from #ESMOBreast21 with https://t.co/ys1d8pDAKO! ➡️https://t.co/AY1GfcIPK8⬅️ #BCSM #Oncology @myESMO https://t.co/Einzp3fFdX
-
-
Mashup Score: 1ESMO Breast 2021: updates on immunotherapy - 3 year(s) ago
In this podcast, Rebecca Dent, MD, FRCP, of the National Cancer Centre Singapore, Rupert Bartsch, MD, of the Medical University of Vienna in Austria, and Marleen Kok, MD, PhD, of the Netherlands Cancer Institute in Amsterdam, discuss key updates on immunotherapies for the treatment of breast cancer, as presented at the 2021 ESMO Breast Cancer Virtual Meeting.
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our latest podcast on key updates in immunotherapy for breast cancer from the #ESMOBreast21 meeting w/ Rebecca Dent, Rupert Bartsch and Marleen Kok 👩⚕️👨⚕️ 🎧 Listen here: https://t.co/wG7FG2ARlq @VJOncology @myESMO @OncoAlert #VJSounds #BreastCancer #BCsm #Immunotherapy
-
-
Mashup Score: 0Enobosarm Induces a 50% CBR in AR+/ER+ Metastatic Breast Cancer That Has Progressed on Palbociclib - 3 year(s) ago
Enobosarm has been shown to induce a clinical benefit rate of 50% at 24 weeks in evaluable patients with measurable metastatic androgren receptor–positive, estrogen receptor–positive, metastatic breast cancer that has progressed on treatment with palbociclib.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results presented during the @myESMO Breast 2021 showed that the CBR at 24 weeks in evaluable patients who received the 9-mg dose of the agent was 32% vs 29% in those who received the 18-mg dose of the agent. @cancermedic #ESMOBreast21 #bcsm https://t.co/SwokLiZUMn
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 3 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast21 has given us plenty to think about and we hope you’ve found it informative too! Catch up on what you might've missed at https://t.co/ys1d8pDAKO @VJOncology @myESMO @OncoAlert #BreastCancer #BCsm #OncoAlert https://t.co/LVC5yG7nxC
-
-
Mashup Score: 3
ESMO Breast: Reassuring safety data for dual anti-HER2 therapy, antibody-drug conjugate
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An investigational antibody-drug conjugate achieved disease control in most of these #breastcancer patients, reported Aditya Bardia, MD, at #ESMOBreast21. By @CBankheadMPT. @myESMO @ABhealer108 https://t.co/vQ97MH3Ywp
-
-
Mashup Score: 0
The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Among 21 evaluable patients, the objective response rate with datopotamab deruxtecan was 43% per blinded independent central review. @ABhealer108 @MassGeneralNews @myESMO #ESMOBreast21 #bcsm https://t.co/Vo89RQXqOU
-
-
Mashup Score: 1Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer - 3 year(s) ago
Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The median progression-free survival was 14.6 weeks with atezolizumab plus carboplatin in evaluable patients with ILC. @LVoorwerk @NKI_nl @myESMO #ESMOBreast21 #bcsm https://t.co/CaYlgRclZi
-
📣Join #ESMOBreast22 for the latest news in #BreastCancer! Get prepared for the meeting with highlights from #ESMOBreast21 at https://t.co/ys1d8pDAKO! ➡️https://t.co/Fg293tFrz7⬅️ #BCSM @myESMO https://t.co/tkEok3tKeP